Baricitinib Safer and Effective for rheumatoid arthritis

Primary tabs

Baricitinib Safer and Effective for rheumatoid arthritis

According to a recent meta-analysis, Baricitinib, a JAK 1 and 2 inhibitor has proven to manage rheumatoid arthritis (RA) effectively but with no significant safety concerns. JAK (Janus kinases), play an important role in RA pathogenesis and Baricitinib, therefore, plays a crucial role in RA control. There's no question regarding  Baricitinib efficacy; however comprehensive efficacy evaluation was still to be assessed. 

Sumit Kunwar and colleagues conducted a meta-analysis to determine the inclusive efficacy and safety profile of Baricitinib. The data for analysis were collected from search engines like Cochrane CENTRAL, EMBASE and PUBMED from 24 September 2017. The abstracts with no full-text publications were not included. The meta-analysis of 2 and 4 mg Baricitinib is achieved via RevMan 5.3 which involved 95% odds ratio and confidence interval.

In the first six months of treatment, 2 mg Baricitinib exhibited significantly achieved ACR20, ACR50 and ACR70 responses as compared to placebo. Likewise, 4 mg  Baricitinib also showed more efficacy as compared to placebo. About safety concerns as compared to placebo, 2 and 4 mg Baricitinib one time a day did not manifest any side effect or adverse events. However, 4 mg Baricitinib exhibited the increased herpes zoster infection instances as compared to placebo. As per overall meta-analysis, Baricitinib shows greater efficacy but not so significant safety concerns during the first 6 months of treatment of RA.


Clinical Rheumatology


The original title of article:

Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials.


Sumit Kunwar et al.

Baricitinib, Rheumatoid Arthritis, Joints, JAK inhibitors, Meta-analysis, Efficacy, Safety, ACR Response Criteria, Odd ratios
Log in or register to post comments